Tags

Type your tag names separated by a space and hit enter

Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly.
Vaccine. 2007 Oct 16; 25(42):7313-21.V

Abstract

Annual circulation of influenza virus coincides with a peak in cardiovascular and pneumonia mortality/morbidity. This study aimed to determine the effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisation due to acute coronary syndrome (ACS), cerebrovascular accident (CVA) and pneumonia in the elderly. Three case-control studies were performed during the 2004-2005 influenza season in three health districts in Valencia, Spain (total elderly [>64 years of age] population: n=105,454). Controls were patients admitted for an acute surgical process or trauma within 10 days of case admission. In total, 159 patients were hospitalised for ACS, 148 for CVA and 242 for pneumonia. The risk of hospitalisation after the start of the influenza season was significantly lower in vaccinated patients compared with non-vaccinated patients (adjusted odds ratios: 0.13 [P=0.013] for ACS; 0.07 [P=0.007] for CVA; 0.31 [P=0.005] for pneumonia). During peak virus circulation, vaccination with MF59-adjuvanted subunit influenza vaccine was associated with an 87% relative risk reduction in hospitalisation for ACS, 93% for CVA, and 69% for pneumonia.

Authors+Show Affiliations

Fundación de la Sociedad Valenciana de Medicina de Familia y Comunitaria, Valencia, Spain. jpuigb@terra.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17889411

Citation

Puig-Barberà, Joan, et al. "Effectiveness of MF59-adjuvanted Subunit Influenza Vaccine in Preventing Hospitalisations for Cardiovascular Disease, Cerebrovascular Disease and Pneumonia in the Elderly." Vaccine, vol. 25, no. 42, 2007, pp. 7313-21.
Puig-Barberà J, Díez-Domingo J, Varea AB, et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine. 2007;25(42):7313-21.
Puig-Barberà, J., Díez-Domingo, J., Varea, A. B., Chavarri, G. S., Rodrigo, J. A., Hoyos, S. P., & Vidal, D. G. (2007). Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine, 25(42), 7313-21.
Puig-Barberà J, et al. Effectiveness of MF59-adjuvanted Subunit Influenza Vaccine in Preventing Hospitalisations for Cardiovascular Disease, Cerebrovascular Disease and Pneumonia in the Elderly. Vaccine. 2007 Oct 16;25(42):7313-21. PubMed PMID: 17889411.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. AU - Puig-Barberà,Joan, AU - Díez-Domingo,Javier, AU - Varea,Angel Belenguer, AU - Chavarri,Germán Schwarz, AU - Rodrigo,José A Lluch, AU - Hoyos,Santiago Pérez, AU - Vidal,David González, Y1 - 2007/09/04/ PY - 2007/07/18/received PY - 2007/08/19/accepted PY - 2007/9/25/pubmed PY - 2007/12/20/medline PY - 2007/9/25/entrez SP - 7313 EP - 21 JF - Vaccine JO - Vaccine VL - 25 IS - 42 N2 - Annual circulation of influenza virus coincides with a peak in cardiovascular and pneumonia mortality/morbidity. This study aimed to determine the effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisation due to acute coronary syndrome (ACS), cerebrovascular accident (CVA) and pneumonia in the elderly. Three case-control studies were performed during the 2004-2005 influenza season in three health districts in Valencia, Spain (total elderly [>64 years of age] population: n=105,454). Controls were patients admitted for an acute surgical process or trauma within 10 days of case admission. In total, 159 patients were hospitalised for ACS, 148 for CVA and 242 for pneumonia. The risk of hospitalisation after the start of the influenza season was significantly lower in vaccinated patients compared with non-vaccinated patients (adjusted odds ratios: 0.13 [P=0.013] for ACS; 0.07 [P=0.007] for CVA; 0.31 [P=0.005] for pneumonia). During peak virus circulation, vaccination with MF59-adjuvanted subunit influenza vaccine was associated with an 87% relative risk reduction in hospitalisation for ACS, 93% for CVA, and 69% for pneumonia. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/17889411/Effectiveness_of_MF59_adjuvanted_subunit_influenza_vaccine_in_preventing_hospitalisations_for_cardiovascular_disease_cerebrovascular_disease_and_pneumonia_in_the_elderly_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(07)00975-9 DB - PRIME DP - Unbound Medicine ER -